The Supply Lines: Which Companies are Making the News?
By

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms). Which companies are making the news?

A roundup of news announcements from DCAT Member Companies in 2023 to date across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging. Which companies are making the news?

Companies making news at DCAT Week 2023 
The Drug, Chemical & Associated Technologies Association (DCAT) held its flagship event, DCAT Week, from March 19 to March 23, 2023, where bio/pharma companies and suppliers convened in New York for high-level business meetings, education programs featuring thought leaders, and networking events. With executives from the bio/pharma industry assembled, DCAT Member Companies took the opportunity to highlight recent news from across the bio/pharmaceutical manufacturing value chain.  

In the March 31, 2023, issue of DCAT Value Chain Insights, we featured companies taking to the podium at the DCAT Member Company Announcement Forum, where senior executives highlighted major news from their companies. Participating in the Forum were: Samsung Biologics, WuXi STA, Bachem, Siegfried, WuXi Biologics, Lonza, Catalent, Thermo Fisher Scientific, Flamma, Porton Pharma, BSP Pharmaceuticals, Granules, Meridian Medical Technologies/Kindeva Drug Delivery, and Incog BioPharma Services. See story, Executives Highlight Expansion Plans at the DCAT Member Company Announcement Forum for a roundup of their news announcements.  

In this issue, DCAT Value Chain Insights highlights other companies making the news in chemical/chemical API manufacturing, biologics manufacturing, formulation development and drug-product manufacturing, end-to-end manufacturing (both drug substances and drug products), and packaging. 

See related stories and the companies making the news below: 

From DCAT Week 2023: Supplier News: Chemicals/Chemical API Manufacturing featuring news from PharmaBlock, Seqens, Polpharma API, Cambrex, Actylis, Avantor, Univar, Procos, Maithri Drugs, Dr. Reddy’s Laboratories, Jubilant Biosys, C2 Pharma, and ChemCon. 

From DCAT Week 2023: Supplier News: Biologics Manufacturing featuring news from BioVectra, Scorpius BioManufacturing, Avid Bioservices, IDT Biologika, Landmark Bio, and Mabion. 

From DCAT Week 2023: Supplier News: Formulation Development/Drug Product Manufacturing featuring news from Evonik, Carbogen Amcis, Vetter, Nanoform, Mikart, Ascendia Pharmaceuticals, Bushu Pharma, and Lifecore Biomedical. 

From DCAT Week 2023: Supplier News: End-to-End (Drug Substance and Drug Product) Mfg with news from CordenPharma and BioDuro Sundia 

From DCAT Week 2023: Supplier News: Packaging featuring news from PCI Pharma Services, Bormioli, and Tedor Pharma Services. 

Recent Feature Articles

Bio/Pharma’s Top 10: Top Deals Thus Far in 2023
By

By
Analysis of the top 10 mergers and acquisitions among bio/pharmaceutical companies thus far in 2023. Which companies and deals are most noteworthy and leading the way? 

Sustainability: Measuring It Globally and in the C-Suite
By

By
How does sustainability and ESG (environmental, social and governance) goals and performance factor into companies’ strategies, operational focus, and financial disclosures? 

Teva’s President and CEO Launches New Pivot to Growth Strategy
By

By
Teva’s President and CEO, Richard Francis, who assumed the helm of Teva in January, outlined this week the company’s new strategic framework to drive growth. The company’s Pivot to Growth strategy encompasses four main pillars to deliver short- and long-term growth from the company’s commercial portfolio and biosimilars, innovative pipeline, generics business, and focused capital allocation. 

Tackling Drug Shortages and Supply-Chain Vulnerabilities in the European Union
By

By
Leaders in the European Union (EU) are addressing ways to mitigate drug shortages and supply-chain vulnerabilities in the EU with 19 EU member states supporting a Critical Medicines Act to reduce the EU’s dependence of non-EU countries for APIs, intermediates and other pharma ingredients. What other actions is the EU taking to mitigate supply-chain vulnerabilities?